Activated Charcoal Oral Suspension shortage
To Be Discontinued 5 presentations · 1 manufacturers · first FDA posting 2026-05-15 · last update 2026-05-15
Manufacturers: Padagis US LLC
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-74) | Padagis US LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 05/15/2026 Updated 05/15/2026 Discontinued 05/15/2026 |
| Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-76) | Padagis US LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 05/15/2026 Updated 05/15/2026 Discontinued 05/15/2026 |
| Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-25) | Padagis US LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 05/15/2026 Updated 05/15/2026 Discontinued 05/15/2026 |
| Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-74) | Padagis US LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 05/15/2026 Updated 05/15/2026 Discontinued 05/15/2026 |
| Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-76) | Padagis US LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 05/15/2026 Updated 05/15/2026 Discontinued 05/15/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)